# VITAL Platform - Business Requirements Document (Gold Standard)

**Document Type:** Business Requirements Document (BRD)
**Version:** 1.0
**Date:** November 16, 2025
**Owner:** Business & Analytics Strategist
**Status:** Week 1-2 Strategic Foundation Deliverable

---

## Document Control

| Version | Date | Author | Changes |
|---------|------|--------|---------|
| 0.1 | Nov 10, 2025 | Business & Analytics Strategist | Initial draft |
| 1.0 | Nov 16, 2025 | Business & Analytics Strategist | Week 1-2 deliverable complete |

**Reviewers:**
- Strategy & Vision Architect (strategic alignment)
- PRD Architect (product requirements alignment)
- Documentation & QA Lead (quality review)

**Cross-References:**
- `VITAL_PLATFORM_VISION_STRATEGY_GOLD_STANDARD.md` - Strategic foundation
- `VITAL_ROI_BUSINESS_CASE.md` - Financial justification
- `VITAL_ANALYTICS_FRAMEWORK.md` - Success measurement

---

## Executive Summary

### Purpose of This Document

This Business Requirements Document (BRD) defines the business needs, objectives, and requirements that the VITAL Platform must satisfy to achieve its strategic vision of transforming Medical Affairs organizations from fixed-capacity teams into infinitely scalable, AI-augmented enterprises.

### Key Business Drivers

1. **Market Opportunity:** $50B+ addressable market across 4 customer segments (Pharma, Biotech, MedTech, CROs)
2. **Customer Pain:** Medical Affairs teams drowning in inquiries with 70-90% of capacity consumed by routine questions
3. **Business Model:** B2B SaaS with enterprise pricing ($5K-$50K/month per customer)
4. **Strategic Goal:** $24M ARR by Year 3 with 500 customers and 31% EBITDA margin
5. **Customer Value:** 5.7x ROI in Year 1, scaling to 10.8x by Year 3

### Critical Business Requirements

**Top 5 Must-Have Capabilities:**
1. Multi-expert AI consultation platform (Ask Expert, Ask Panel, Ask Committee)
2. BYOAI orchestration (customers integrate proprietary AI agents)
3. Enterprise-grade security & compliance (SOC 2, HIPAA, GDPR, 21 CFR Part 11)
4. Multi-tenant architecture with complete data isolation
5. Real-time ROI measurement & reporting

### Success Criteria

**Platform will be considered successful when:**
- 50 enterprise customers by end of Year 1 (2026)
- 200 customers by end of Year 2 (2027)
- 500 customers by end of Year 3 (2028)
- Customer ROI consistently exceeds 5x
- Net Revenue Retention (NRR) exceeds 120%
- Time-to-Value (TTV) under 30 days

---

# PART I: BUSINESS CONTEXT

## 1. Market Opportunity

### 1.1 Total Addressable Market (TAM)

**Primary Market: Medical Affairs Technology**

```
Pharmaceutical Companies (Global)
├─ Large Pharma (Top 50): 50 companies × $500K-$2M/year = $50M-$100M
├─ Mid-size Pharma (51-200): 150 companies × $200K-$800K/year = $30M-$120M
├─ Small Pharma (201-1000): 800 companies × $60K-$200K/year = $48M-$160M
└─ TOTAL PHARMA: ~$128M-$380M

Biotechnology Companies
├─ Large Biotech (Top 100): 100 companies × $300K-$1M/year = $30M-$100M
├─ Mid-size Biotech: 300 companies × $100K-$400K/year = $30M-$120M
└─ TOTAL BIOTECH: ~$60M-$220M

Medical Device Companies
├─ Large MedTech (Top 50): 50 companies × $400K-$1.5M/year = $20M-$75M
├─ Mid-size MedTech: 200 companies × $150K-$600K/year = $30M-$120M
└─ TOTAL MEDTECH: ~$50M-$195M

CROs & Service Providers
└─ Top 200 CROs: 200 companies × $100K-$500K/year = $20M-$100M

TOTAL TAM (Conservative): $258M/year
TOTAL TAM (Optimistic): $895M/year
REALISTIC 3-YEAR TARGET: $50M-$100M (10% market penetration)
```

**Expansion Markets (Year 3+):**
- Healthcare providers & hospital systems ($1B+)
- Regulatory affairs technology ($500M+)
- Clinical development platforms ($2B+)
- Medical communications ($300M+)

**Total Expansion TAM: $50B+ (AI-augmented knowledge work across life sciences)**

### 1.2 Market Trends & Drivers

**Trend 1: AI Adoption in Life Sciences**
- 87% of pharma companies investing in AI initiatives (Deloitte 2024)
- Average AI budget: $15M-$50M annually for large pharma
- Pain point: Disconnected AI initiatives, no orchestration platform

**Trend 2: Medical Affairs Transformation**
- Medical Affairs evolving from reactive to strategic partner
- 65% of pharma executives cite Medical Affairs as competitive differentiator
- Critical challenge: Scaling expertise without proportional headcount growth

**Trend 3: Regulatory Pressure**
- FDA guidance on AI/ML in healthcare (2024)
- Need for transparent, auditable AI decision-making
- Compliance overhead increasing 15-20% annually

**Trend 4: Remote/Hybrid Work**
- 78% of Medical Affairs teams now hybrid or remote
- Demand for asynchronous expert consultation tools
- Knowledge silos exacerbated by distributed teams

**Trend 5: Data Explosion**
- 10,000+ clinical trials initiated annually (ClinicalTrials.gov)
- Doubling of scientific publications every 9 years
- Impossible for human experts to stay current without AI assistance

### 1.3 Target Customer Segments

**Segment 1: Large Pharmaceutical Companies (Primary Target, Year 1-2)**

```
Profile:
├─ Company Size: $5B-$50B+ annual revenue
├─ Medical Affairs Team: 50-500 professionals
├─ Annual Budget: $50M-$500M for Medical Affairs
├─ Geographic Footprint: Global (50+ countries)
├─ Product Portfolio: 10-50 approved products
└─ AI Maturity: Advanced (existing AI initiatives)

Pain Points:
├─ 1,500-5,000 monthly HCP inquiries overwhelming Medical Science Liaisons (MSLs)
├─ 70-90% of MSL capacity consumed by routine questions
├─ Inconsistent responses across geographies
├─ No centralized knowledge management
└─ Difficulty demonstrating Medical Affairs ROI

VITAL Value Proposition:
├─ Automate 60-80% of routine inquiries
├─ Free up 20-30 hours/week per MSL for strategic work
├─ Ensure consistent, compliant responses globally
├─ Real-time ROI measurement & reporting
└─ 5.7x ROI in Year 1

Pricing: $15K-$50K/month ($180K-$600K/year)
Year 1 Target: 30 customers
Year 3 Target: 150 customers
```

**Segment 2: Mid-Size Biotech Companies (Secondary Target, Year 1-3)**

```
Profile:
├─ Company Size: $500M-$5B annual revenue
├─ Medical Affairs Team: 10-50 professionals
├─ Annual Budget: $5M-$50M for Medical Affairs
├─ Geographic Footprint: US/EU focus
├─ Product Portfolio: 2-10 approved products or late-stage pipeline
└─ AI Maturity: Emerging (pilot projects)

Pain Points:
├─ Small teams, high inquiry volume (500-2,000/month)
├─ Cannot justify hiring more MSLs
├─ Need to compete with larger pharma on Medical Affairs excellence
├─ Limited budget for technology
└─ Rapid growth straining existing processes

VITAL Value Proposition:
├─ "Infinite MSL team" without headcount costs
├─ Enterprise-grade capabilities at mid-market price
├─ Fast time-to-value (30 days)
├─ Scales with company growth
└─ 7.2x ROI in Year 1 (higher than large pharma due to labor cost savings)

Pricing: $8K-$20K/month ($96K-$240K/year)
Year 1 Target: 15 customers
Year 3 Target: 250 customers
```

**Segment 3: Medical Technology Companies (Tertiary Target, Year 2-3)**

```
Profile:
├─ Company Size: $1B-$20B annual revenue
├─ Clinical Affairs Team: 20-200 professionals
├─ Annual Budget: $10M-$100M for Clinical/Medical Affairs
├─ Geographic Footprint: Global or regional
├─ Product Portfolio: 5-50 approved devices
└─ AI Maturity: Moderate (exploring AI)

Pain Points:
├─ Technical product questions from clinicians
├─ Post-market surveillance & safety reporting
├─ Need for clinical evidence generation support
├─ Regulatory compliance (FDA, MDR, etc.)
└─ Educational content creation at scale

VITAL Value Proposition:
├─ AI-powered clinical support for device-related queries
├─ Automated post-market surveillance workflows
├─ Evidence synthesis & literature review automation
├─ Compliance documentation & audit trail
└─ 6.5x ROI in Year 1

Pricing: $10K-$30K/month ($120K-$360K/year)
Year 1 Target: 5 customers
Year 3 Target: 100 customers
```

**Segment 4: CROs & Service Providers (Expansion Target, Year 2-3)**

```
Profile:
├─ Company Size: $100M-$5B annual revenue
├─ Medical/Clinical Team: 50-500 professionals
├─ Annual Budget: $5M-$50M for Medical Affairs equivalent
├─ Geographic Footprint: Global
├─ Client Portfolio: 20-200 pharma/biotech clients
└─ AI Maturity: Varied (dependent on client needs)

Pain Points:
├─ Need to provide Medical Affairs services to multiple clients
├─ Each client requires separate expertise & knowledge base
├─ High cost of maintaining deep therapeutic area expertise
├─ Difficulty scaling to new clients without proportional hiring
└─ Client demand for AI-augmented services

VITAL Value Proposition:
├─ Multi-tenant platform supporting multiple client engagements
├─ Rapid onboarding of new therapeutic areas
├─ White-label capability for CRO branding
├─ Usage-based pricing aligned with client billing
└─ 8.1x ROI in Year 1 (CROs pass costs through to clients)

Pricing: $12K-$40K/month ($144K-$480K/year)
Year 1 Target: 0 customers (not targeting yet)
Year 3 Target: 50 customers
```

### 1.4 Competitive Landscape

**Competitive Set 1: Medical Information Platforms**

```
Veeva Medical
├─ Strengths: Market leader, integrated with Veeva CRM, strong brand
├─ Weaknesses: Not AI-native, limited automation, high cost
├─ Pricing: $50K-$200K/year
└─ VITAL Advantage: 10x more automation, 1/3 the cost, BYOAI capability

Zinc Maps
├─ Strengths: Good content management, HCP engagement features
├─ Weaknesses: No AI consultation, manual inquiry handling
├─ Pricing: $30K-$100K/year
└─ VITAL Advantage: AI-first platform, autonomous inquiry handling

Antidote / MI Navigator
├─ Strengths: Established player, workflow automation
├─ Weaknesses: Legacy technology, limited AI, no multi-agent orchestration
├─ Pricing: $40K-$120K/year
└─ VITAL Advantage: Modern AI architecture, infinitely scalable
```

**Competitive Set 2: Enterprise AI Platforms**

```
Microsoft Copilot for M365
├─ Strengths: Integrated with Office 365, familiar UX, enterprise-ready
├─ Weaknesses: Generic (not pharma-specific), no compliance features, privacy concerns
├─ Pricing: $30/user/month
└─ VITAL Advantage: Purpose-built for Medical Affairs, compliant, auditable

ChatGPT Enterprise (OpenAI)
├─ Strengths: Best-in-class LLM, fast innovation, brand recognition
├─ Weaknesses: Generic, no domain expertise, compliance unclear
├─ Pricing: $60-$100/user/month (estimated)
└─ VITAL Advantage: Medical Affairs expertise, regulatory compliance, BYOAI

Anthropic Claude for Enterprise
├─ Strengths: Strong reasoning, long context, ethical AI focus
├─ Weaknesses: Generic platform, no industry workflows
├─ Pricing: Custom enterprise pricing
└─ VITAL Advantage: Domain-specific agents, orchestration, proven ROI
```

**Competitive Set 3: AI Agent Platforms**

```
LangChain / LangSmith
├─ Strengths: Developer-friendly, flexible, open-source roots
├─ Weaknesses: Requires in-house AI team, no turnkey solution
├─ Pricing: $39-$99/user/month + LLM costs
└─ VITAL Advantage: Turnkey Medical Affairs solution, no AI expertise required

CrewAI / AutoGPT
├─ Strengths: Multi-agent frameworks, autonomous workflows
├─ Weaknesses: Developer tools (not end-user platform), no compliance
├─ Pricing: Open-source + hosting costs
└─ VITAL Advantage: Business user interface, enterprise-ready, compliant

Zapier / Make.com (workflow automation)
├─ Strengths: Easy to use, 1000s of integrations
├─ Weaknesses: Not AI-native, no domain expertise, limited intelligence
├─ Pricing: $20-$100/user/month
└─ VITAL Advantage: AI-first, Medical Affairs workflows out-of-box
```

**Competitive Set 4: Knowledge Management Platforms**

```
Guru / Notion AI
├─ Strengths: Good knowledge capture, team collaboration
├─ Weaknesses: Not AI-consultation platform, manual Q&A
├─ Pricing: $10-$30/user/month
└─ VITAL Advantage: Autonomous AI consultation, not just knowledge storage

Coveo / Lucidworks (enterprise search)
├─ Strengths: Powerful search, AI-assisted retrieval
├─ Weaknesses: Search-centric (not consultation), no agent orchestration
├─ Pricing: $50K-$300K/year
└─ VITAL Advantage: Active AI agents, not passive search
```

**Competitive Set 5: Internal Build (Make vs. Buy Decision)**

```
"We'll build it ourselves"
├─ Strengths: Custom fit, full control, no vendor lock-in
├─ Weaknesses: 18-24 month timeline, $2M-$5M cost, ongoing maintenance
├─ Pricing: $2M-$5M initial + $500K-$1M/year maintenance
└─ VITAL Advantage: 30-day time-to-value, 1/10th the cost, continuous innovation

Why Customers Choose VITAL Over Build:
├─ Time to market: 30 days vs. 18-24 months
├─ Total cost: $180K/year vs. $2M+ initial + $500K/year
├─ Risk: Proven platform vs. unproven internal project
├─ Opportunity cost: IT team can focus on core differentiators
└─ Continuous innovation: Monthly product releases vs. slow internal roadmap
```

### 1.5 Business Problem Statement

**The Medical Affairs Capacity Crisis**

Medical Affairs teams in pharmaceutical, biotech, and medical device companies face an existential scaling problem:

**Current State:**
- Medical Science Liaisons (MSLs) receive 30-50 inquiries/month from healthcare professionals (HCPs)
- Each inquiry requires 2-8 hours to research, consult experts, and provide compliant response
- 70-90% of MSL capacity consumed by routine, repeatable questions
- Only 10-30% of capacity available for strategic activities (KOL engagement, advisory boards, insights generation)
- Teams cannot scale linearly: hiring an MSL costs $200K-$300K/year fully loaded
- Geographic coverage gaps: impossible to have local experts in every market
- Knowledge silos: expertise trapped in individual expert heads
- Inconsistent responses: same question answered differently by different MSLs
- No ROI measurement: Medical Affairs cannot quantify business value delivered

**Business Impact:**
- Lost revenue opportunities: $5M-$50M/year per large pharma company (delayed HCP education = delayed prescribing)
- Compliance risk: $1M-$10M/year (inconsistent responses lead to regulatory issues)
- Employee burnout: 35% MSL turnover rate (industry average)
- Competitive disadvantage: companies with better Medical Affairs support win market share
- Inability to scale: company growth requires proportional Medical Affairs headcount growth

**Root Causes:**
1. **Fixed capacity model**: Teams are sized based on headcount, not capability
2. **Manual, reactive processes**: Every inquiry handled individually by humans
3. **Knowledge not productized**: Expertise exists as tribal knowledge, not as reusable AI agents
4. **No orchestration layer**: Multiple AI tools exist but don't work together
5. **Measurement gap**: No way to prove Medical Affairs ROI to CFO/CEO

**The VITAL Solution:**

Transform Medical Affairs from a **fixed-capacity cost center** into an **infinitely scalable value driver** through AI-augmented expert consultation:

```
Before VITAL:                    After VITAL:
═══════════════                  ═══════════════
50 MSLs                          50 MSLs + 136 AI Agents
2,500 inquiries/month handled    10,000+ inquiries/month handled
70-90% capacity on routine       20-30% capacity on routine (AI handles rest)
10-30% capacity on strategic     70-80% capacity on strategic
$10M-$15M annual cost           $10.5M-$15.5M annual cost (+$500K for VITAL)
No ROI measurement              Real-time ROI dashboard (5.7x Year 1)
Inconsistent responses          100% consistent, compliant responses
18-24 months to scale to new    30 days to scale to new markets
markets
```

**Business Value Delivered:**
- 4x inquiry handling capacity without proportional headcount growth
- 50-70% cost reduction per inquiry handled
- 100% response consistency & compliance
- 5.7x ROI in Year 1, scaling to 10.8x by Year 3
- Real-time business impact measurement
- Ability to scale infinitely without linear cost increase

---

## 2. Strategic Alignment

### 2.1 Alignment with Corporate Strategy

**VITAL's Strategic Vision:**

> "Transform Medical Affairs from fixed-capacity teams into infinitely scalable, AI-augmented organizations that amplify human genius rather than replace it."

**Strategic Pillars:**

**Pillar 1: Human-in-Control AI**
- All AI recommendations reviewed by human experts before delivery
- Experts maintain authority and accountability
- AI amplifies expertise, doesn't replace it
- Aligns with: Customer trust, regulatory compliance, professional ethics

**Pillar 2: Enterprise-Grade Platform**
- SOC 2 Type II, HIPAA, GDPR, 21 CFR Part 11 compliant from Day 1
- Multi-tenant architecture with complete data isolation
- 99.9% uptime SLA
- Aligns with: Customer risk tolerance, IT procurement requirements

**Pillar 3: Measurable Business Value**
- Real-time ROI measurement built into platform
- Customer value equation: (Time Saved × Hourly Rate) + (Decisions Improved × Decision Value) + (Risk Avoided × Risk Cost) - VITAL Cost
- Target: 5x+ ROI for every customer
- Aligns with: CFO/CEO approval criteria, renewal/expansion decisions

**Pillar 4: Open Ecosystem (BYOAI)**
- Customers integrate proprietary AI agents alongside VITAL agents
- No vendor lock-in to specific LLM providers
- API-first architecture for extensibility
- Aligns with: Customer desire for flexibility, avoid obsolescence

**Pillar 5: Continuous Innovation**
- Monthly product releases (new agents, features, integrations)
- Leverage rapid AI/ML advancement from OpenAI, Anthropic, Google, etc.
- Customer Success team proactively drives adoption
- Aligns with: Customer expectation for cutting-edge technology

### 2.2 Strategic Goals (3-Year Horizon)

**Financial Goals:**

```
Year 1 (2026):
├─ ARR: $1.2M (50 customers)
├─ Gross Margin: 86%
├─ EBITDA: -$1.6M (investment phase)
├─ Burn Rate: $135K/month
└─ Cash Runway: 18 months

Year 2 (2027):
├─ ARR: $6.0M (200 customers)
├─ Gross Margin: 86%
├─ EBITDA: -$1.4M (Q4 profitable)
├─ Burn Rate: $120K/month → $0/month
└─ Cash Runway: Break-even Q4

Year 3 (2028):
├─ ARR: $24.0M (500 customers)
├─ Gross Margin: 86%
├─ EBITDA: +$7.4M (31% margin)
├─ Free Cash Flow: +$6.8M
└─ Valuation: $100M-$150M (4-6x ARR)
```

**Customer Goals:**

```
Year 1: 50 enterprise customers
├─ 30 large pharma ($15K-$50K/month)
├─ 15 mid-size biotech ($8K-$20K/month)
├─ 5 medical device companies ($10K-$30K/month)
└─ Average: $24K/month = $288K/year

Year 2: 200 customers (150 net new)
├─ Segment mix shifts toward mid-market
├─ First CRO customers
└─ Average: $30K/month = $360K/year (upsell effect)

Year 3: 500 customers (300 net new)
├─ Land-and-expand driving growth
├─ Multi-product adoption
└─ Average: $48K/month = $576K/year (2x Year 1 ARPU)
```

**Product Goals:**

```
Year 1:
├─ Core Platform (Ask Expert, Ask Panel, BYOAI Orchestration)
├─ 3 Tier 1 agent categories (136 agents)
├─ 10 enterprise integrations (Veeva, Salesforce, etc.)
├─ SOC 2 Type II certification
└─ Mobile apps (iOS, Android)

Year 2:
├─ AI Advisory Board (Ask Committee)
├─ Insights & Analytics Engine
├─ White-label capability (for CROs)
├─ 25 enterprise integrations
└─ FedRAMP certification (US gov't)

Year 3:
├─ Multi-modal AI (voice, video consultation)
├─ Predictive inquiry routing
├─ Auto-agent generation from documents
├─ 50 enterprise integrations
└─ International expansion (EU, APAC data residency)
```

**Market Goals:**

```
Year 1: Establish category leadership
├─ "AI-Augmented Medical Affairs Platform" category creation
├─ Thought leadership (10 conference presentations, 5 whitepapers)
├─ Analyst recognition (Gartner, Forrester awareness)
└─ Customer case studies (5 published ROI stories)

Year 2: Market dominance
├─ #1 market share in AI-powered Medical Affairs
├─ Industry awards (Best Medical Affairs Technology)
├─ Strategic partnerships (Veeva, IQVIA, etc.)
└─ Customer advocacy program (20 reference customers)

Year 3: Platform ecosystem
├─ Third-party agent marketplace
├─ Partner channel (consulting firms, system integrators)
├─ Industry standard for Medical Affairs AI
└─ Acquisition interest from strategic buyers
```

### 2.3 Business Objectives

**Primary Objective 1: Achieve Product-Market Fit (Year 1, Q1-Q2)**

**Definition of Product-Market Fit:**
- 30+ enterprise customers actively using platform
- 80%+ customer satisfaction (NPS > 50)
- 90%+ customer retention
- Organic referrals (30%+ of new customers from word-of-mouth)
- Customer ROI consistently exceeds 5x

**Success Metrics:**
- Weekly Active Users (WAU): 70%+ of licensed users
- Consultations per user per week: 3+
- Time-to-Value: <30 days from contract to first consultation
- Customer Health Score: 80+ (out of 100)

**Key Activities:**
- Intensive customer discovery (100 interviews with MSLs, Medical Directors)
- Rapid iteration on core workflows (Ask Expert, Ask Panel)
- White-glove onboarding for first 30 customers
- Weekly customer feedback sessions
- Monthly product releases based on customer input

**Primary Objective 2: Achieve $1.2M ARR (Year 1, Full Year)**

**Revenue Breakdown:**
```
Large Pharma (30 customers × $300K/year avg): $9.0M pipeline → $900K closed ARR
Mid-Size Biotech (15 customers × $150K/year avg): $2.25M pipeline → $225K closed ARR
MedTech (5 customers × $180K/year avg): $900K pipeline → $90K closed ARR
TOTAL TARGET: $12.15M pipeline → $1.215M ARR (10% win rate)
```

**Success Metrics:**
- Sales pipeline: $12M+ (10x coverage)
- Win rate: 10%+ (competitive for enterprise SaaS)
- Sales cycle: 90-120 days (typical for Medical Affairs procurement)
- Average deal size: $24K/month ($288K/year)

**Key Activities:**
- Build sales team (2 AEs by Q2)
- Develop sales playbook & collateral
- Establish partnerships with Veeva, IQVIA for co-selling
- Attend 5 major industry conferences (DIA, MAPS, etc.)
- Launch customer referral program

**Primary Objective 3: Achieve Operational Profitability (Year 2, Q4)**

**Path to Profitability:**
```
Q1 2027: $1.5M ARR, -$400K EBITDA (burn $133K/month)
Q2 2027: $3.0M ARR, -$350K EBITDA (burn $117K/month)
Q3 2027: $4.5M ARR, -$200K EBITDA (burn $67K/month)
Q4 2027: $6.0M ARR, +$50K EBITDA (profitable!)
```

**Success Metrics:**
- Gross margin: 86%+ (maintain)
- CAC Payback: <3 months
- LTV/CAC Ratio: >25x
- Burn multiple: <0.5 (efficient growth)

**Key Activities:**
- Optimize customer acquisition (shift from outbound to inbound)
- Implement product-led growth motions (free trial, self-serve tier)
- Improve operational efficiency (automation, AI-powered support)
- Expand average deal size through upsells (multi-product, seat expansion)

**Secondary Objective 1: Build World-Class Team (Year 1-2)**

**Hiring Plan:**
```
Year 1 (End State: 15 FTEs):
├─ Leadership: CEO (Hicham), CTO, VP Sales, VP Customer Success
├─ Engineering: 4 engineers (2 frontend, 2 backend)
├─ Product: 1 Product Manager
├─ Sales: 2 Account Executives
├─ Customer Success: 2 CSMs
├─ Operations: 1 Finance/Ops Manager
└─ TOTAL: 13 FTEs

Year 2 (End State: 30 FTEs):
├─ Engineering: +6 (total 10)
├─ Sales: +4 (total 6)
├─ Customer Success: +4 (total 6)
├─ Product: +2 (total 3)
├─ Marketing: +2 (new function)
├─ Operations: +2 (total 3)
└─ TOTAL: 30 FTEs (+15 from Year 1)
```

**Success Metrics:**
- Glassdoor rating: 4.5+
- Employee NPS: 70+
- Retention rate: 90%+ (key roles)
- Time-to-productivity: <30 days

**Secondary Objective 2: Establish Thought Leadership (Year 1-3)**

**Content & Community:**
- Publish 12 industry whitepapers (1/month)
- Present at 10 conferences/year
- Host quarterly "AI in Medical Affairs" virtual summit
- Build LinkedIn community (10K+ followers by Year 3)
- Launch podcast: "The AI-Augmented Medical Affairs Leader"

**Success Metrics:**
- Website traffic: 10K visitors/month by Year 1, 50K by Year 3
- Inbound leads: 30%+ of pipeline from content marketing
- Brand awareness: 80% of target customers aware of VITAL by Year 3
- Analyst recognition: Gartner Cool Vendor, Forrester Wave inclusion

---

# PART II: BUSINESS REQUIREMENTS

## 3. Functional Requirements

### 3.1 Core Platform Capabilities

**FR-001: Multi-Expert AI Consultation**

**Business Need:**
Medical Affairs professionals need instant access to AI-powered expert consultation across 136 specialized agents representing deep domain expertise in therapeutic areas, regulatory topics, and operational functions.

**Functional Requirements:**

```
FR-001.1: Ask Expert (1-on-1 AI Consultation)
├─ User selects expert from 136-agent registry
├─ User poses question in natural language
├─ AI agent generates response with citations
├─ Human expert reviews & approves response (Human-in-Control)
├─ System logs interaction for audit trail
└─ Response delivered within 4-hour SLA (90% of inquiries)

FR-001.2: Ask Panel (Multi-Expert Collaboration)
├─ User poses question to panel of 2-5 experts
├─ Each AI agent provides independent perspective
├─ System synthesizes responses into coherent recommendation
├─ Human expert reviews synthesized response
├─ Dissenting opinions clearly documented
└─ Panel response delivered within 8-hour SLA

FR-001.3: Ask Committee (AI Advisory Board)
├─ Complex, multi-dimensional questions (regulatory + medical + commercial)
├─ Committee of 5-12 experts with chairperson
├─ Structured deliberation process (research → discussion → vote → synthesis)
├─ Human oversight at each phase
├─ Committee report delivered within 24-hour SLA
└─ Full transparency into reasoning process
```

**Business Value:**
- Reduce time to expert answer from 24-72 hours to 4-8 hours (70-90% reduction)
- Ensure multi-disciplinary perspective on complex questions
- Provide audit trail for regulatory compliance

**Acceptance Criteria:**
- 90% of Ask Expert inquiries answered within 4 hours
- 85% of Ask Panel inquiries answered within 8 hours
- 100% of responses include citations to source material
- 100% of responses reviewed by human expert before delivery

---

**FR-002: BYOAI Orchestration (Bring Your Own AI)**

**Business Need:**
Enterprise customers have proprietary AI agents (trained on internal data, custom models) that they want to integrate with VITAL platform. Must support seamless orchestration between VITAL agents and customer agents.

**Functional Requirements:**

```
FR-002.1: Agent Registration & Discovery
├─ Customer registers custom AI agent via API
├─ Agent metadata: Name, description, capabilities, API endpoint, auth method
├─ System validates agent compatibility (OpenAPI spec, response format)
├─ Agent appears in user's expert registry alongside VITAL agents
└─ Customer maintains full control over agent lifecycle

FR-002.2: Unified Consultation Experience
├─ User experience identical whether consulting VITAL or customer agent
├─ System routes inquiry to appropriate agent based on expertise
├─ Customer agents invoked via secure API call
├─ Response handling consistent (review, approval, audit trail)
└─ Performance metrics tracked for all agents (VITAL + customer)

FR-002.3: Multi-Agent Workflows
├─ Customer creates workflows combining VITAL + custom agents
├─ Example: VITAL Medical Agent → Customer's Internal Policy Agent → VITAL Regulatory Agent
├─ Workflow designer with visual editor
├─ Conditional logic (if/then routing based on response content)
└─ Workflow templates for common patterns
```

**Business Value:**
- Differentiation: Only platform supporting true BYOAI orchestration
- Customer lock-in: Deep integration with customer's AI ecosystem
- Network effects: More customer agents = more valuable platform
- No vendor lock-in: Customers retain ownership of proprietary IP

**Acceptance Criteria:**
- Customer can register custom agent in <5 minutes via UI or API
- Custom agents respond within same SLA as VITAL agents
- 100% compatibility with OpenAI-compatible API specification
- Zero data leakage between customer agents and VITAL agents

---

**FR-003: Enterprise Security & Compliance**

**Business Need:**
Pharmaceutical companies cannot use AI platforms that don't meet stringent regulatory, security, and data privacy requirements. VITAL must be compliant from Day 1.

**Functional Requirements:**

```
FR-003.1: Multi-Tenant Data Isolation
├─ Complete logical separation of customer data (Row-Level Security)
├─ No shared infrastructure between customers (dedicated schemas)
├─ Customer data encrypted at rest (AES-256) and in transit (TLS 1.3)
├─ Customer-managed encryption keys (CMEK) option for enterprise tier
└─ Data residency options (US, EU, APAC)

FR-003.2: Audit Trail & Compliance Logging
├─ Every consultation logged with full context
├─ Immutable audit log (append-only, cryptographically signed)
├─ Retention policy: 7 years (21 CFR Part 11 requirement)
├─ Export capability for regulatory submissions
└─ Real-time compliance dashboard

FR-003.3: Access Control & Authentication
├─ SSO integration (SAML 2.0, OAuth 2.0, OIDC)
├─ Role-based access control (RBAC) with custom roles
├─ Multi-factor authentication (MFA) required for production access
├─ Session management (auto-logout after 30 min inactivity)
└─ Privileged access management (PAM) for admin functions

FR-003.4: Certifications & Attestations
├─ SOC 2 Type II (security, availability, confidentiality)
├─ HIPAA compliant (BAA available)
├─ GDPR compliant (EU data residency, right to erasure)
├─ 21 CFR Part 11 compliant (electronic records & signatures)
└─ ISO 27001 certified (Year 2 target)
```

**Business Value:**
- Reduce security review cycle from 6-12 months to 1-2 months
- Enable sales to enterprise customers (non-negotiable requirement)
- Reduce customer perceived risk
- Premium pricing for enterprise tier (+30% vs. standard tier)

**Acceptance Criteria:**
- Pass enterprise security review at 3 Fortune 500 pharma companies
- SOC 2 Type II certification by end of Year 1
- Zero security incidents in first 3 years
- <24 hour response time to security vulnerabilities

---

**FR-004: Real-Time ROI Measurement**

**Business Need:**
CFOs and Medical Affairs leaders need proof that VITAL is delivering measurable business value. Must quantify ROI in real-time, not quarterly retrospectives.

**Functional Requirements:**

```
FR-004.1: Automated Value Tracking
├─ Time saved per consultation (user self-report or auto-calculate)
├─ Hourly rate of user (configurable per role)
├─ Decision value (impact scoring for strategic decisions)
├─ Risk avoided (compliance risk, safety signal detection)
└─ Real-time ROI calculation using VITAL Value Equation™

FR-004.2: Executive ROI Dashboard
├─ ROI multiple (current: 5.7x, trend over time)
├─ Total value delivered (cumulative $ amount)
├─ Value by category (time saved, decisions improved, risk avoided)
├─ Value by user, department, therapeutic area
└─ Projection: ROI next 12 months based on usage trend

FR-004.3: Benchmark & Comparisons
├─ Compare customer ROI to industry benchmarks
├─ Cohort analysis (similar companies, same industry)
├─ ROI improvement recommendations (underutilized features)
└─ Cost-benefit analysis vs. alternatives (hiring MSLs, legacy systems)

FR-004.4: ROI Reporting & Export
├─ Quarterly Business Review (QBR) report auto-generated
├─ Export to PowerPoint, PDF, Excel
├─ Customizable reports for different stakeholders (CFO, VP Medical Affairs, CSuite)
└─ API access for integration with customer BI tools
```

**Business Value:**
- Increase renewal rate from 85% to 95% (prove ongoing value)
- Enable expansion sales (show ROI, upsell more seats/features)
- Reduce churn risk (proactive alerts when ROI drops)
- Differentiation: Only platform with built-in ROI measurement

**Acceptance Criteria:**
- ROI dashboard updates in real-time (<5 min latency)
- 100% of customers see positive ROI (>1x) within 90 days
- 90% of customers see >5x ROI within 6 months
- QBR report generation: <1 minute (automated)

---

### 3.2 User Experience Requirements

**FR-005: Intuitive User Interface**

**Business Need:**
Medical Affairs professionals are not AI/ML experts. Platform must be as easy to use as asking a colleague a question.

**Functional Requirements:**

```
FR-005.1: Conversational Interface
├─ Natural language input (no training required)
├─ Suggested questions / prompts for new users
├─ Autocomplete based on previous inquiries
├─ Voice input option (mobile app)
└─ Multi-language support (English, Spanish, German, French, Japanese, Chinese)

FR-005.2: Expert Discovery & Selection
├─ Browse experts by category (therapeutic area, function)
├─ Search experts by keyword or symptom
├─ Smart recommendations ("Based on your question, consider asking...")
├─ Expert profiles (expertise, qualifications, sample responses)
└─ Favorite experts for quick access

FR-005.3: Response Quality & Clarity
├─ Responses in plain language (avoid jargon unless appropriate)
├─ Structured format (summary, detailed answer, citations, next steps)
├─ Confidence score (how certain is the AI agent?)
├─ Alternative perspectives (dissenting opinions if applicable)
└─ Follow-up question suggestions

FR-005.4: Mobile-First Design
├─ Responsive web app (works on any device)
├─ Native iOS & Android apps
├─ Offline mode (save inquiries, sync when online)
├─ Push notifications (response ready, approval required)
└─ Accessibility (WCAG 2.1 AA compliant)
```

**Acceptance Criteria:**
- Time to first consultation: <5 minutes for new user
- User satisfaction (CSAT): 4.5+ out of 5
- Support ticket volume: <5% of active users per month (low friction)
- Mobile app rating: 4.5+ stars (iOS App Store, Google Play)

---

**FR-006: Collaboration & Knowledge Sharing**

**Business Need:**
Medical Affairs teams need to share insights, build institutional knowledge, and collaborate across geographies. Platform must facilitate teamwork.

**Functional Requirements:**

```
FR-006.1: Consultation Sharing
├─ Share consultation with colleagues (in-platform)
├─ Privacy controls (share with specific users, teams, or organization-wide)
├─ Comment on shared consultations (discussion thread)
├─ Upvote/downvote (signal high-quality consultations)
└─ Analytics: Most shared consultations, trending topics

FR-006.2: Team Workspaces
├─ Create teams (by therapeutic area, geography, function)
├─ Team consultation history (shared knowledge base)
├─ Team-specific agents (trained on team's documents)
├─ Team performance metrics (ROI, usage, quality)
└─ Team admin controls (membership, permissions)

FR-006.3: Knowledge Base Building
├─ Convert high-quality consultations into knowledge base articles
├─ Curation workflow (propose → review → approve → publish)
├─ Knowledge base search (separate from live consultation)
├─ Version control (track updates to articles)
└─ Permissions (who can read, edit, approve)

FR-006.4: Expert Network
├─ Directory of human experts in organization
├─ Expert availability status (available, busy, out-of-office)
├─ Request human review (escalate AI response to human expert)
├─ Expert performance metrics (response time, quality scores)
└─ Expert recognition (leaderboard, badges)
```

**Acceptance Criteria:**
- 40%+ of consultations shared with at least one colleague
- 60%+ of users active in at least one team workspace
- Knowledge base grows by 10+ articles/month (curated content)
- Expert response time: <2 hours for escalated consultations (during business hours)

---

### 3.3 Integration Requirements

**FR-007: Enterprise System Integrations**

**Business Need:**
VITAL must fit seamlessly into customer's existing technology stack. Cannot require rip-and-replace of current systems.

**Functional Requirements:**

```
FR-007.1: CRM Integration (Veeva CRM, Salesforce)
├─ Sync consultation activity to CRM (associate with HCP account)
├─ Trigger consultation from CRM (e.g., HCP inquiry logged in Veeva)
├─ Surface VITAL insights in CRM (AI-generated HCP profile enrichment)
├─ Bi-directional data sync (real-time or scheduled)
└─ OAuth 2.0 authentication

FR-007.2: Medical Information Platform Integration (Veeva Vault MedComms)
├─ Import approved content into VITAL knowledge base
├─ Citation to Vault documents in AI responses
├─ Update notification (when Vault content changes, retrain AI agents)
├─ Audit trail sync (VITAL consultation → Vault inquiry record)
└─ API-based integration

FR-007.3: Single Sign-On (SSO) Integration
├─ SAML 2.0 (Okta, Azure AD, Ping Identity)
├─ OAuth 2.0 / OIDC
├─ LDAP / Active Directory (for on-prem deployments)
├─ Just-in-Time (JIT) user provisioning
└─ SCIM for user lifecycle management

FR-007.4: Data Warehouse / BI Integration
├─ Export consultation data to customer data warehouse (Snowflake, Databricks, BigQuery)
├─ Pre-built connectors for common BI tools (Tableau, Power BI, Looker)
├─ API for custom integrations
├─ Real-time data streaming (Kafka, Pub/Sub) or batch export (daily/hourly)
└─ Data schema documentation

FR-007.5: Content Management System (CMS) Integration
├─ Import content from SharePoint, Confluence, Google Drive
├─ Auto-index new content (periodic scan or webhook-triggered)
├─ Content freshness monitoring (alert when content outdated)
├─ Citation links back to source CMS
└─ Access control sync (respect CMS permissions in VITAL)
```

**Business Value:**
- Reduce implementation time from 90 days to 30 days (faster time-to-value)
- Increase user adoption (no context switching between systems)
- Enhance data value (VITAL data enriches customer BI/analytics)
- Competitive advantage (only platform with deep Veeva integration)

**Acceptance Criteria:**
- 10 pre-built integrations available by end of Year 1
- 90% of enterprise customers use at least 2 integrations
- Integration setup time: <4 hours per integration (with documentation)
- Zero data loss during bi-directional sync

---

## 4. Process Requirements

### 4.1 Inquiry Management Process

**PR-001: End-to-End Inquiry Workflow**

**Business Need:**
Standardize how inquiries are received, processed, reviewed, and delivered to ensure consistency, compliance, and quality.

**Process Flow:**

```
PHASE 1: INQUIRY INTAKE
┌─────────────────────────────────────────────┐
│ 1. User submits inquiry                     │
│    ├─ Via VITAL UI (web or mobile app)      │
│    ├─ Via email (inquiry@vital.ai)          │
│    ├─ Via CRM integration (Veeva)           │
│    └─ Via API (programmatic submission)     │
│                                             │
│ 2. System classifies inquiry                │
│    ├─ Urgency (routine, urgent, emergency)  │
│    ├─ Complexity (simple, moderate, complex)│
│    ├─ Topic (therapeutic area, function)    │
│    └─ Recommended expert(s)                 │
│                                             │
│ 3. Route to expert or panel                │
│    ├─ Auto-route based on classification    │
│    ├─ User manually selects expert          │
│    └─ System suggests panel for complex Q   │
└─────────────────────────────────────────────┘
                    ↓
PHASE 2: AI RESPONSE GENERATION
┌─────────────────────────────────────────────┐
│ 4. AI agent generates response              │
│    ├─ RAG pipeline (retrieve relevant docs) │
│    ├─ LLM synthesis (generate answer)       │
│    ├─ Citation generation (link to sources) │
│    ├─ Quality checks (factual accuracy)     │
│    └─ Compliance checks (regulatory flags)  │
│                                             │
│ 5. Multi-agent collaboration (if panel)    │
│    ├─ Each agent generates independent view │
│    ├─ Synthesis agent combines perspectives │
│    ├─ Conflict resolution (flag dissent)    │
│    └─ Final response draft                  │
└─────────────────────────────────────────────┘
                    ↓
PHASE 3: HUMAN REVIEW & APPROVAL
┌─────────────────────────────────────────────┐
│ 6. Human expert notified (push, email)     │
│    ├─ Response preview in notification      │
│    ├─ One-click approval for routine        │
│    └─ Full review interface for complex     │
│                                             │
│ 7. Expert reviews response                 │
│    ├─ Factual accuracy check                │
│    ├─ Compliance review (on-label, etc.)    │
│    ├─ Tone & professionalism check          │
│    ├─ Citation verification                 │
│    └─ Edit if needed (inline editing)       │
│                                             │
│ 8. Expert takes action                     │
│    ├─ APPROVE → Deliver to user             │
│    ├─ EDIT & APPROVE → Save changes, deliver│
│    ├─ REJECT → Send back to AI for revision │
│    └─ ESCALATE → Route to senior expert     │
└─────────────────────────────────────────────┘
                    ↓
PHASE 4: DELIVERY & FOLLOW-UP
┌─────────────────────────────────────────────┐
│ 9. Response delivered to user              │
│    ├─ In-app notification                   │
│    ├─ Email notification (with link)        │
│    ├─ SMS (for urgent inquiries)            │
│    └─ CRM update (if inquiry from CRM)      │
│                                             │
│ 10. User feedback collection               │
│    ├─ Rating (1-5 stars)                    │
│    ├─ Helpful / Not Helpful                 │
│    ├─ Comment (optional)                    │
│    └─ Follow-up question (optional)         │
│                                             │
│ 11. Audit trail & analytics                │
│    ├─ Log full interaction (immutable)      │
│    ├─ Calculate metrics (time, quality, ROI)│
│    ├─ Update dashboards (real-time)         │
│    └─ Identify improvement opportunities    │
└─────────────────────────────────────────────┘
```

**Service Level Agreements (SLAs):**

| Inquiry Type | Target Response Time | Human Review SLA | Delivery SLA |
|--------------|---------------------|------------------|--------------|
| **Routine (70%)** | AI: 2 min | Human: 2 hours | Total: 4 hours |
| **Moderate (25%)** | AI: 5 min | Human: 4 hours | Total: 8 hours |
| **Complex (5%)** | AI: 15 min | Human: 12 hours | Total: 24 hours |
| **Emergency** | AI: 1 min | Human: 30 min | Total: 1 hour |

**Business Requirements:**
- 90% of inquiries meet SLA
- 95% approval rate on first AI response (low rejection rate)
- 100% human review before delivery (Human-in-Control principle)
- <5% escalation rate (AI + expert handles 95% without senior involvement)

---

**PR-002: Quality Assurance Process**

**Business Need:**
Maintain consistently high quality across all AI responses to build user trust and ensure regulatory compliance.

**Process Components:**

```
1. Pre-Delivery Quality Checks (Automated)
   ├─ Factual accuracy (cross-reference with knowledge base)
   ├─ Citation completeness (every claim has source)
   ├─ Regulatory compliance (flag off-label, unapproved claims)
   ├─ Tone analysis (professional, empathetic, appropriate)
   └─ Completeness check (did AI answer the full question?)

2. Human Expert Review (Required)
   ├─ Expert training & certification (before allowed to approve responses)
   ├─ Review checklist (standardized criteria)
   ├─ Edit capability (inline editing with track changes)
   ├─ Rejection with feedback (AI learns from mistakes)
   └─ Escalation path (when expert unsure)

3. Post-Delivery Quality Monitoring (Continuous)
   ├─ User feedback analysis (identify low-rated responses)
   ├─ Expert feedback analysis (high rejection rate = AI retraining needed)
   ├─ Spot audits (random sample review by QA team)
   ├─ Compliance audits (quarterly regulatory review)
   └─ AI model performance tracking (accuracy, hallucination rate)

4. Continuous Improvement Loop
   ├─ Weekly QA review meeting (discuss failures, patterns)
   ├─ Monthly AI model retraining (incorporate feedback)
   ├─ Quarterly knowledge base updates (refresh content)
   ├─ Annual compliance certification (external audit)
   └─ Customer QBRs (discuss quality metrics, improvement plans)
```

**Quality Metrics:**

| Metric | Target | Measurement |
|--------|--------|-------------|
| **First-Pass Approval Rate** | >95% | % of AI responses approved without edits |
| **User Satisfaction (CSAT)** | >4.5/5 | Average rating on delivered responses |
| **Factual Accuracy** | >99% | % of responses with zero factual errors (audit) |
| **Compliance Rate** | 100% | % of responses meeting regulatory standards |
| **Expert Confidence** | >90% | % of experts "very confident" in AI responses |

---

### 4.2 Customer Onboarding Process

**PR-003: 30-Day Onboarding to Value**

**Business Need:**
Reduce time-to-value from industry average of 90-120 days to VITAL target of 30 days. Fast onboarding drives customer satisfaction and reduces churn risk.

**Onboarding Phases:**

```
WEEK 1: KICKOFF & FOUNDATION
┌─────────────────────────────────────────────────────────┐
│ Day 1-2: Kickoff & Planning                             │
│ ├─ Kickoff call (customer + VITAL team)                 │
│ ├─ Define success criteria (what does "go-live" mean?)  │
│ ├─ Identify key stakeholders (champions, executives)    │
│ ├─ Assign VITAL Customer Success Manager (CSM)          │
│ └─ Deliverable: Onboarding plan (30-day roadmap)        │
│                                                          │
│ Day 3-5: Technical Setup                                │
│ ├─ Provision VITAL tenant (multi-tenant instance)       │
│ ├─ Configure SSO (integrate with customer IdP)          │
│ ├─ Set up user roles & permissions (RBAC)               │
│ ├─ Integrate with CRM / other systems (if applicable)   │
│ └─ Deliverable: VITAL environment ready, SSO working    │
│                                                          │
│ Day 6-7: Knowledge Base Seeding                         │
│ ├─ Customer provides approved content (PDFs, docs)      │
│ ├─ VITAL team uploads & indexes content                 │
│ ├─ AI agents trained on customer content                │
│ ├─ Quality check (sample queries, validate responses)   │
│ └─ Deliverable: Customer-specific knowledge base ready  │
└─────────────────────────────────────────────────────────┘
                         ↓
WEEK 2: PILOT & TRAINING
┌─────────────────────────────────────────────────────────┐
│ Day 8-10: Pilot User Training                           │
│ ├─ Identify 10-20 pilot users (early adopters)          │
│ ├─ Live training session (2 hours, hands-on)            │
│ ├─ Provide training materials (videos, quick ref guide) │
│ ├─ Pilot users submit first 10 consultations            │
│ └─ Deliverable: Pilot users actively using VITAL        │
│                                                          │
│ Day 11-14: Pilot Iteration & Feedback                   │
│ ├─ Daily stand-ups with pilot users (15 min check-ins)  │
│ ├─ Collect feedback (what's working, what's not)        │
│ ├─ Rapid iteration (fix issues, tune AI responses)      │
│ ├─ Measure pilot metrics (usage, satisfaction, ROI)     │
│ └─ Deliverable: Pilot success (>80% user satisfaction)  │
└─────────────────────────────────────────────────────────┘
                         ↓
WEEK 3: ROLLOUT PREPARATION
┌─────────────────────────────────────────────────────────┐
│ Day 15-17: Rollout Planning                             │
│ ├─ Define rollout cohorts (phased or big-bang?)         │
│ ├─ Create internal communications (email, Slack, etc.)  │
│ ├─ Prepare "train-the-trainer" materials                │
│ ├─ Set up support channels (Slack, email, help desk)    │
│ └─ Deliverable: Rollout plan approved by customer       │
│                                                          │
│ Day 18-21: Rollout Execution                            │
│ ├─ Send announcement to all users                       │
│ ├─ Conduct training sessions (multiple sessions for TZs)│
│ ├─ Activate all user accounts                           │
│ ├─ Monitor adoption (who's logging in, who's not)       │
│ └─ Deliverable: 70%+ of users logged in, 50%+ active    │
└─────────────────────────────────────────────────────────┘
                         ↓
WEEK 4: OPTIMIZATION & GO-LIVE
┌─────────────────────────────────────────────────────────┐
│ Day 22-25: Adoption Drive                               │
│ ├─ Proactive outreach to inactive users                 │
│ ├─ Showcase success stories (internal champions)        │
│ ├─ Office hours (daily drop-in sessions for Q&A)        │
│ ├─ Gamification (leaderboard, badges for usage)         │
│ └─ Deliverable: 80%+ user activation rate               │
│                                                          │
│ Day 26-28: Performance Optimization                     │
│ ├─ Analyze usage patterns (which experts most used?)    │
│ ├─ Tune AI models (improve low-rated responses)         │
│ ├─ Add content (fill knowledge gaps identified)         │
│ ├─ Configure workflows (automate common patterns)       │
│ └─ Deliverable: 90%+ first-pass approval rate           │
│                                                          │
│ Day 29-30: Go-Live Certification                        │
│ ├─ Review success criteria (from Day 1)                 │
│ ├─ Measure outcomes (usage, ROI, satisfaction)          │
│ ├─ Executive business review (celebrate success!)       │
│ ├─ Transition to steady-state support (CSM ongoing)     │
│ └─ Deliverable: GO-LIVE CERTIFIED ✅                    │
└─────────────────────────────────────────────────────────┘
```

**Onboarding Success Criteria:**

| Metric | Target | Definition |
|--------|--------|------------|
| **Time-to-Value** | <30 days | Days from contract to "go-live certification" |
| **User Activation** | >80% | % of licensed users who log in during Week 4 |
| **Active Usage** | >70% | % of users who submit ≥1 consultation/week |
| **User Satisfaction** | >4.0/5 | CSAT score at end of onboarding |
| **ROI Proof Point** | >3x | Measured ROI by Day 30 (early indicator of 5.7x Year 1) |

**VITAL Team Responsibilities:**

| Role | Responsibilities |
|------|------------------|
| **Customer Success Manager (CSM)** | Overall onboarding owner, weekly check-ins, executive sponsor relationship |
| **Implementation Engineer** | Technical setup, integrations, SSO configuration |
| **AI Training Specialist** | Knowledge base seeding, AI model tuning, quality assurance |
| **Customer Trainer** | User training, create training materials, office hours |
| **Support Engineer** | Tier 2/3 support during onboarding, rapid issue resolution |

**Customer Team Responsibilities:**

| Role | Responsibilities |
|------|------------------|
| **Executive Sponsor** | Provide air cover, remove blockers, celebrate success |
| **Project Manager** | Coordinate customer team, manage timeline, communicate internally |
| **Medical Affairs Lead** | Define use cases, identify pilot users, validate AI responses |
| **IT Contact** | SSO setup, integration support, security review |
| **Training Champions** | Lead peer training, answer user questions, evangelize platform |

---

### 4.3 Customer Success & Support Process

**PR-004: Proactive Customer Success Management**

**Business Need:**
Ensure every customer achieves ROI, renews contract, and expands usage over time. Proactive (not reactive) approach to customer success.

**Customer Lifecycle Stages:**

```
STAGE 1: ONBOARDING (Day 1-30)
├─ Goal: Achieve go-live certification
├─ CSM Touch Points: Daily (Week 1), 3x/week (Week 2-4)
├─ Key Activities: Setup, training, adoption drive
└─ Success Metric: 80%+ user activation, 3x+ ROI

STAGE 2: ADOPTION (Month 2-6)
├─ Goal: Drive deep usage & habit formation
├─ CSM Touch Points: Weekly (Month 2-3), Bi-weekly (Month 4-6)
├─ Key Activities:
│   ├─ Feature adoption campaigns (promote underutilized features)
│   ├─ Best practices sharing (learn from high-performing users)
│   ├─ Quarterly Business Review (QBR) at Month 3, Month 6
│   └─ Early renewal conversation (if strong adoption)
└─ Success Metric: 70%+ WAU, 5x+ ROI, NPS > 50

STAGE 3: EXPANSION (Month 7-12)
├─ Goal: Increase ARPU through upsells
├─ CSM Touch Points: Monthly + ad-hoc
├─ Key Activities:
│   ├─ Identify expansion opportunities (more seats, premium features, add-ons)
│   ├─ Executive Business Review (EBR) with C-suite
│   ├─ Co-marketing opportunities (case study, webinar, conference)
│   └─ Renewal preparation (120-day process)
└─ Success Metric: 30%+ upsell, 95%+ renewal likelihood

STAGE 4: RENEWAL & ADVOCACY (Month 11-24+)
├─ Goal: Renew contract, expand further, become reference customer
├─ CSM Touch Points: Quarterly + renewal period (intensive)
├─ Key Activities:
│   ├─ Renewal negotiation (120-day lead time)
│   ├─ Multi-year contract discussion (Year 2-3 commitment)
│   ├─ Reference customer program (case study, analyst calls)
│   ├─ Customer Advisory Board (CAB) invitation
│   └─ Product co-innovation (customer influences roadmap)
└─ Success Metric: 100% renewal, 3-year contract, public case study
```

**Customer Health Scoring:**

VITAL uses a predictive health score (0-100) to identify at-risk customers early:

```
HEALTH SCORE COMPONENTS:

1. Usage Score (40% weight)
   ├─ Weekly Active Users (WAU) vs. licensed seats
   ├─ Consultations per user per week
   ├─ Feature adoption (using >5 features)
   └─ Trend: Usage increasing or decreasing?

2. Business Value Score (30% weight)
   ├─ Measured ROI (vs. 5x target)
   ├─ Time-to-value (achieved in <30 days?)
   ├─ User satisfaction (CSAT, NPS)
   └─ Executive sponsorship (engaged or disengaged?)

3. Relationship Score (20% weight)
   ├─ CSM touch point frequency (meeting cadence)
   ├─ Responsiveness (do they reply to emails promptly?)
   ├─ Collaboration (do they provide feedback, attend training?)
   └─ Escalations (any unresolved issues?)

4. Strategic Fit Score (10% weight)
   ├─ Company growth trajectory (growing or shrinking?)
   ├─ Budget availability (can they afford renewal/expansion?)
   ├─ Competitive threats (are competitors circling?)
   └─ Executive turnover (did champion leave?)

HEALTH SCORE BANDS:

├─ 80-100 (GREEN): Thriving, likely to renew & expand
├─ 60-79 (YELLOW): Healthy but needs attention
├─ 40-59 (ORANGE): At-risk, proactive intervention required
└─ 0-39 (RED): High churn risk, escalate to leadership
```

**Proactive Intervention Playbooks:**

| Health Score | CSM Action Plan |
|--------------|-----------------|
| **GREEN (80-100)** | • Request case study or reference<br>• Introduce expansion SKUs<br>• Nominate for Customer Advisory Board<br>• Celebrate success (award, recognition) |
| **YELLOW (60-79)** | • Schedule QBR to discuss usage trends<br>• Identify barriers to adoption<br>• Offer training refresher<br>• Introduce new features to re-engage |
| **ORANGE (40-59)** | • Immediate intervention (call within 24 hours)<br>• Conduct "rescue" assessment (what's wrong?)<br>• Create action plan with customer<br>• Exec-to-exec engagement (VP CS → Customer exec) |
| **RED (0-39)** | • Escalate to VP Customer Success + CEO<br>• Emergency business review<br>• Consider discount/credit to buy time<br>• Last-ditch save attempt or graceful off-boarding |

---

## 5. Compliance & Regulatory Requirements

### 5.1 Data Privacy & Security

**CR-001: GDPR Compliance (EU Customers)**

**Requirements:**
- Lawful basis for processing (customer consent, contract, legitimate interest)
- Data subject rights: Access, rectification, erasure, portability, restrict processing
- Data Protection Impact Assessment (DPIA) for high-risk processing
- Data Processing Agreement (DPA) with customers
- EU data residency option (data never leaves EU)
- Breach notification (<72 hours to supervisory authority)

**Implementation:**
- GDPR compliance module in platform (user rights self-service)
- DPA template (standard Schrems II-compliant DPA)
- EU data center (AWS Frankfurt or GCP Belgium)
- Privacy policy & cookie consent (website)
- Designated Data Protection Officer (DPO)

---

**CR-002: HIPAA Compliance (US Healthcare Customers)**

**Requirements:**
- Business Associate Agreement (BAA) with covered entities
- Administrative safeguards (security official, training, incident response)
- Physical safeguards (data center security, device controls)
- Technical safeguards (encryption, access control, audit logs)
- Protected Health Information (PHI) handling (minimal necessary, de-identification)

**Implementation:**
- HIPAA-compliant infrastructure (AWS GovCloud or Azure for Healthcare)
- BAA template (standard HIPAA BAA)
- Encryption: AES-256 at rest, TLS 1.3 in transit
- Audit logging: All PHI access logged and retained 7 years
- Annual HIPAA compliance audit (external firm)

---

**CR-003: 21 CFR Part 11 Compliance (FDA Regulated)**

**Requirements:**
- Electronic signatures (validated, unique, non-reusable)
- Audit trails (immutable, timestamped, who/what/when/why)
- System validation (IQ/OQ/PQ documentation)
- Access control (role-based, least privilege)
- Data integrity (ALCOA+ principles: Attributable, Legible, Contemporaneous, Original, Accurate)

**Implementation:**
- E-signature module (cryptographic signing)
- Immutable audit log (blockchain-backed or append-only database)
- Validation documentation package (for customer QA review)
- Access control matrix (RBAC with audit trail)
- Annual 21 CFR Part 11 audit (external firm)

---

### 5.2 AI/ML Governance

**CR-004: AI Transparency & Explainability**

**Business Need:**
Customers (especially regulated pharma) need to understand how AI makes decisions to satisfy regulators and maintain trust.

**Requirements:**

```
1. Explainability
   ├─ Every AI response includes reasoning (chain-of-thought)
   ├─ Citation to source documents (traceability)
   ├─ Confidence score (how certain is the AI?)
   └─ Alternative perspectives (if applicable)

2. Bias Detection & Mitigation
   ├─ Regular bias audits (gender, race, age, geography)
   ├─ Fairness metrics (disparate impact, equal opportunity)
   ├─ Bias mitigation techniques (re-weighting, adversarial debiasing)
   └─ Diverse training data (representative of global Medical Affairs)

3. Model Governance
   ├─ Model registry (which model version used for each response)
   ├─ Model validation (accuracy, precision, recall, F1 score)
   ├─ Model versioning (track changes, rollback capability)
   └─ Model retirement (deprecate underperforming models)

4. Human Oversight
   ├─ 100% human review before response delivery (Human-in-Control)
   ├─ Human-in-the-Loop for model training (expert labeling)
   ├─ Escalation path (when AI uncertain, route to senior expert)
   └─ Override capability (human can always override AI)
```

**Documentation:**
- AI Transparency Report (annual, public)
- AI Ethics Policy (internal governance)
- Model Cards (for each AI agent, describing capabilities, limitations, biases)
- Explainability Guide (for customers, how to interpret AI responses)

---

**CR-005: Content & Response Compliance**

**Business Need:**
AI responses must comply with pharmaceutical regulations (FDA, EMA, PMDA, etc.) to avoid regulatory enforcement, fines, or consent decrees.

**Requirements:**

```
1. On-Label Content Only
   ├─ AI agents trained only on approved product labeling
   ├─ Off-label detection (flag unapproved uses, indications, populations)
   ├─ Reject off-label inquiries (with compliant explanation)
   └─ Audit trail (all off-label flags logged)

2. Fair Balance (US Promotional Regulations)
   ├─ Present risks alongside benefits
   ├─ Avoid minimizing or omitting risk information
   ├─ Provide full prescribing information (PI) link
   └─ Fair balance checker (automated scan of response)

3. Substantiation
   ├─ Every clinical claim cited to published study or approved labeling
   ├─ Strength of evidence indicated (Level I-V)
   ├─ Avoid absolute claims ("always", "never") unless substantiated
   └─ Update content when new data available (proactive monitoring)

4. Adverse Event Reporting
   ├─ Detect adverse event mentions in inquiries
   ├─ Auto-generate AE report (MedDRA coding, E2B format)
   ├─ Route to pharmacovigilance team (within 24 hours)
   └─ Comply with expedited reporting timelines (15-day, 7-day)

5. Medical Information Best Practices
   ├─ Respond only to unsolicited requests (no proactive promotion)
   ├─ Do not recommend specific products (non-promotional)
   ├─ Provide balanced information (competitive products if asked)
   └─ Document inquiry in Medical Information system (Veeva Vault, etc.)
```

**Compliance Monitoring:**
- Real-time compliance checks (automated scanning)
- Weekly compliance review (random sample of responses)
- Quarterly regulatory audit (external counsel review)
- Annual submission to regulators (if required, e.g., FDA annual report)

---

## 6. Stakeholder Analysis

### 6.1 Internal Stakeholders (VITAL Team)

| Stakeholder | Role | Interests | Influence | Engagement Strategy |
|-------------|------|-----------|-----------|---------------------|
| **CEO (Hicham)** | Founder & Chief Executive | Company success, fundraising, strategic vision | Very High | Weekly 1:1, involved in all major decisions |
| **CTO** | Technology leader | Product quality, engineering excellence, technical innovation | Very High | Daily collaboration, joint product roadmap |
| **VP Sales** | Revenue leader | Hit sales targets, pipeline growth, deal closure | High | Weekly pipeline review, sales enablement |
| **VP Customer Success** | Retention & expansion leader | Customer satisfaction, renewals, NRR >120% | High | Weekly metrics review, customer escalations |
| **VP Product** | Product strategy | Product-market fit, customer feedback, roadmap prioritization | High | Weekly product review, customer discovery |
| **Engineering Team** | Builders | Interesting technical challenges, career growth, work-life balance | Medium | Sprint planning, retros, tech talks |
| **Sales Team** | Quota carriers | Comp plan, leads, sales tools, win rate | Medium | Weekly team meeting, monthly 1:1s |
| **Customer Success Team** | Customer advocates | Customer success, manageable workload, career growth | Medium | Weekly team meeting, monthly 1:1s |

---

### 6.2 External Stakeholders (Customer Organization)

| Stakeholder | Role | Interests | Influence | Engagement Strategy |
|-------------|------|-----------|-----------|---------------------|
| **CFO** | Financial decision-maker | ROI, cost savings, budget impact | Very High | Executive business reviews, ROI dashboards, financial models |
| **VP/Head of Medical Affairs** | Business owner | Solve capacity crisis, demonstrate MA value, team satisfaction | Very High | Monthly strategic reviews, thought leadership content, peer network |
| **Medical Science Liaisons (MSLs)** | End users | Easier job, more time for strategic work, career development | High | Training, adoption campaigns, user community, recognition programs |
| **CIO / IT** | Technology gatekeeper | Security, integration, scalability, support burden | High | Technical documentation, security reviews, IT roadmap alignment |
| **Compliance / Legal** | Risk manager | Regulatory compliance, audit readiness, liability mitigation | High | Compliance documentation, audit support, risk assessments |
| **Procurement** | Contract negotiator | Cost, contract terms, vendor management | Medium | Pricing transparency, flexible contracts, SLAs |
| **HR / L&D** | Training & development | Employee adoption, change management, skill development | Medium | Training materials, change management support, certifications |
| **Pharmacovigilance** | Safety monitoring | AE detection & reporting, regulatory compliance | Medium | Integration with PV systems, AE workflows, compliance |

---

### 6.3 Ecosystem Stakeholders

| Stakeholder | Relationship | Interests | Engagement Strategy |
|-------------|--------------|-----------|---------------------|
| **Veeva Systems** | Strategic partner | Co-sell VITAL + Veeva CRM, joint customers, integration | Partnership agreement, co-marketing, joint sales calls |
| **IQVIA** | Potential partner | Data & analytics services, consulting | Explore partnership (IQVIA data → VITAL AI agents) |
| **Industry Associations (DIA, MAPS)** | Thought leadership platform | Member value, industry advancement | Sponsorships, speaking, board membership |
| **Investors (VCs, Angels)** | Funding sources | ROI, growth, exit potential | Quarterly investor updates, annual investor day |
| **Regulators (FDA, EMA)** | Regulatory authorities | Patient safety, compliance, innovation | Proactive engagement, transparency, industry working groups |
| **Analysts (Gartner, Forrester)** | Market influencers | Accurate market data, vendor differentiation | Briefings, inquiries, Magic Quadrant participation |
| **Customers' Customers (HCPs)** | Indirect beneficiaries | Timely, accurate medical information | Indirectly (through customer success), case studies |

---

## 7. Success Metrics & KPIs

### 7.1 Business Metrics (Company Performance)

| Category | Metric | Year 1 Target | Year 2 Target | Year 3 Target | Measurement Frequency |
|----------|--------|---------------|---------------|---------------|----------------------|
| **Revenue** | ARR | $1.2M | $6.0M | $24.0M | Monthly |
| | ARPU (Avg Revenue Per User) | $24K/year | $30K/year | $48K/year | Monthly |
| | Upsell Rate | 10% | 20% | 30% | Quarterly |
| | New ARR | $1.2M | $4.8M | $18.0M | Monthly |
| | Expansion ARR | $0 | $1.2M | $6.0M | Monthly |
| **Profitability** | Gross Margin | 86% | 86% | 86% | Monthly |
| | EBITDA Margin | -133% | -23% | +31% | Monthly |
| | Free Cash Flow | -$1.6M | -$1.4M | +$6.8M | Monthly |
| | Burn Multiple | 1.3 | 0.3 | N/A (profitable) | Monthly |
| **Efficiency** | CAC (Customer Acquisition Cost) | $24K | $20K | $18K | Monthly |
| | CAC Payback Period | 12 months | 8 months | 4.5 months | Monthly |
| | LTV/CAC Ratio | 16.7x | 22.5x | 31.1x | Quarterly |
| | Magic Number | 1.0 | 2.0 | 3.0 | Quarterly |

---

### 7.2 Customer Metrics (Customer Success)

| Category | Metric | Target | Measurement |
|----------|--------|--------|-------------|
| **Acquisition** | Sales Cycle Length | 90 days | Days from first meeting to contract signed |
| | Win Rate | 25% | % of qualified opps that close-won |
| | Pipeline Coverage | 3x | Pipeline $ / Quarterly quota |
| **Activation** | Time-to-Value | 30 days | Days from contract to go-live certification |
| | User Activation Rate | 80% | % of licensed users who log in during onboarding |
| | Feature Adoption | 60% | % of users using >3 features in Month 1 |
| **Engagement** | Weekly Active Users (WAU) | 70% | % of licensed users active each week |
| | Daily Active Users (DAU) | 40% | % of licensed users active each day |
| | Consultations per User per Week | 3+ | Average consultations submitted per user |
| | Stickiness (DAU/MAU) | 57% | DAU divided by MAU (measures habit formation) |
| **Value** | Customer ROI | 5.7x Year 1 | Measured via VITAL Value Equation™ |
| | Hours Amplified (North Star) | 50K Year 1 | Total hours of human genius amplified |
| | Customer Satisfaction (CSAT) | 4.5/5 | Post-consultation rating |
| | Net Promoter Score (NPS) | 60+ | % promoters - % detractors |
| **Retention** | Gross Retention Rate (GRR) | 90% | % of ARR retained (excluding expansion) |
| | Net Retention Rate (NRR) | 120% | % of ARR retained + expansion |
| | Logo Churn | <10% | % of customers who cancel annually |
| | Seat Expansion | 25% | % growth in seats per customer |

---

### 7.3 Product Metrics (Platform Performance)

| Category | Metric | Target | Measurement |
|----------|--------|--------|-------------|
| **Quality** | First-Pass Approval Rate | 95% | % of AI responses approved without edits |
| | User Rating (Avg) | 4.5/5 | Average star rating on consultations |
| | Factual Accuracy | 99%+ | % of responses with zero factual errors |
| | Compliance Rate | 100% | % of responses meeting regulatory standards |
| **Performance** | Response Time (P50) | <3 min | Median time from inquiry to AI response |
| | Response Time (P95) | <10 min | 95th percentile response time |
| | Uptime | 99.9% | % of time platform available |
| | Error Rate | <0.1% | % of requests that fail |
| **Adoption** | Feature Adoption (Core) | 90% | % of users using Ask Expert |
| | Feature Adoption (Advanced) | 40% | % of users using Ask Panel or Ask Committee |
| | API Usage | 25% | % of customers using BYOAI feature |
| | Mobile Usage | 35% | % of consultations via mobile app |
| **Growth** | Monthly Active Experts | 136 | Total AI agents available |
| | Custom Agents (BYOAI) | 10+ per customer | Avg custom agents per enterprise customer |
| | Integrations Active | 3 per customer | Avg integrations per customer |
| | Knowledge Base Size | 10K docs/customer | Avg documents in customer knowledge base |

---

## 8. Risks & Mitigation Strategies

### 8.1 Business Risks

**RISK-001: Slow Enterprise Sales Cycles**

**Description:** Enterprise Medical Affairs sales cycles average 120-180 days, slower than VITAL target of 90 days.

**Impact:** Miss Year 1 ARR target ($1.2M), burn more cash, extend runway needs.

**Probability:** Medium (40%)

**Mitigation:**
- Develop product-led growth (PLG) motion: Free trial for small teams
- Land-and-expand: Start with pilot (10 users), expand after proof
- Executive sponsorship program: Accelerate deals with C-suite engagement
- Channel partnerships: Veeva co-sell shortens cycle (their relationship + our product)

---

**RISK-002: Customer Concentration Risk**

**Description:** Top 3 customers represent >40% of ARR. If one churns, material business impact.

**Impact:** Revenue volatility, investor concern, valuation impact.

**Probability:** Medium (30%)

**Mitigation:**
- Diversification: Target 50 customers in Year 1 (no single customer >10% ARR)
- Multi-year contracts: Lock in top customers with 2-3 year commitments
- Account management excellence: White-glove service for top 10 customers
- Expansion focus: Reduce concentration by growing other accounts

---

**RISK-003: Competitive Response (Incumbents)**

**Description:** Veeva, Zinc, or other Medical Affairs incumbents copy VITAL AI features.

**Impact:** Reduced differentiation, price pressure, slower growth.

**Probability:** High (60%)

**Mitigation:**
- Speed: Ship features faster than incumbents (monthly releases vs. their annual)
- Integration: Deep integration with Veeva (partnership = competitive moat)
- BYOAI: Unique capability incumbents can't easily copy (requires open architecture)
- Switching costs: Once customer integrated, high friction to switch
- Brand: "AI-native platform" vs. "legacy platform adding AI"

---

### 8.2 Product & Technology Risks

**RISK-004: AI Hallucination / Inaccuracy**

**Description:** AI agents generate factually incorrect or misleading responses, damaging customer trust.

**Impact:** Loss of customer confidence, regulatory scrutiny, potential patient harm.

**Probability:** Medium (40%)

**Mitigation:**
- Human-in-Control: 100% human review before response delivery
- RAG architecture: Ground responses in factual documents (reduce hallucination)
- Confidence scoring: Flag low-confidence responses for extra review
- Continuous monitoring: Track accuracy, retrain models when accuracy drops
- Insurance: Errors & omissions insurance ($5M-$10M coverage)

---

**RISK-005: Data Privacy Breach**

**Description:** Security incident exposes customer data (PHI, proprietary content).

**Impact:** Regulatory fines ($10M-$50M), lawsuits, reputational damage, customer churn.

**Probability:** Low (10%)

**Mitigation:**
- Security-first architecture: Multi-tenant isolation, encryption, access controls
- Compliance certifications: SOC 2 Type II, HIPAA, ISO 27001
- Penetration testing: Quarterly pen tests by external firms
- Incident response plan: 24-hour breach notification process
- Cyber insurance: $10M-$25M coverage

---

**RISK-006: Dependence on Third-Party LLMs**

**Description:** OpenAI, Anthropic, or Google changes pricing, API access, or discontinues service.

**Impact:** Cost increase, service disruption, need to re-architect platform.

**Probability:** Medium (30%)

**Mitigation:**
- Multi-LLM strategy: Support OpenAI, Anthropic, Google, Azure OpenAI
- Model abstraction layer: Easy to swap LLM providers
- Cost monitoring: Track LLM costs, optimize prompts to reduce token usage
- Negotiate enterprise agreements: Lock in pricing with annual commits

---

### 8.3 Market & Regulatory Risks

**RISK-007: Regulatory Crackdown on AI in Pharma**

**Description:** FDA or EMA issues guidance restricting AI use in Medical Affairs.

**Impact:** Product roadmap changes, customer concerns, slower adoption.

**Probability:** Low (20%)

**Mitigation:**
- Proactive engagement: Participate in FDA AI working groups
- Transparency: Publish AI transparency report, demonstrate responsible AI
- Human-in-Control: Emphasize human oversight (compliant with expected regulations)
- Adaptability: Design platform to easily adjust to new regulatory requirements

---

**RISK-008: Market Not Ready for AI**

**Description:** Medical Affairs teams reluctant to adopt AI due to distrust, change resistance, or lack of understanding.

**Impact:** Slow adoption, high churn, need for extensive change management.

**Probability:** Medium (35%)

**Mitigation:**
- Education: Thought leadership content, webinars, industry presentations
- Change management: Include change mgmt services in onboarding
- Proof points: Case studies demonstrating ROI, user testimonials
- Free trials: Let customers experience value before committing
- Human-in-Control messaging: "AI amplifies experts, doesn't replace them"

---

## 9. Assumptions & Dependencies

### 9.1 Key Assumptions

**Business Assumptions:**
- Medical Affairs capacity crisis is real and urgent (validated through customer discovery)
- Customers have budget for AI solutions ($100K-$500K/year discretionary spending)
- Procurement process takes 90-120 days (typical for enterprise SaaS)
- Renewal rate >90% if customer achieves 5x+ ROI
- Net Revenue Retention (NRR) >120% through seat expansion and upsells

**Market Assumptions:**
- Medical Affairs technology market growing 15-20% annually
- AI adoption in pharma accelerating (87% of companies investing)
- No regulatory prohibitions on AI in Medical Affairs
- Competitive landscape remains fragmented (no dominant AI player emerges)
- Strategic buyers (Veeva, IQVIA, Oracle) interested in acquisition by Year 3

**Product Assumptions:**
- LLM technology continues to improve (accuracy, cost, speed)
- Customer content quality sufficient for AI training (not all garbage in)
- Users willing to provide feedback to train AI (Human-in-the-Loop)
- 30-day time-to-value achievable with white-glove onboarding
- ROI measurable and attributable to VITAL (not confounded by other factors)

**Technology Assumptions:**
- Cloud infrastructure costs decline 10-15% annually (Moore's Law for cloud)
- LLM API costs decline as competition increases (OpenAI, Anthropic, Google)
- No catastrophic AI failures (major hallucination scandal affecting all LLMs)
- Third-party LLM providers remain available and reliable
- VITAL engineering team can ship monthly releases (high velocity)

### 9.2 Key Dependencies

**External Dependencies:**
- **LLM Providers (OpenAI, Anthropic, Google):** Platform relies on third-party LLMs
- **Cloud Infrastructure (AWS, GCP):** Platform hosted on public cloud
- **Integration Partners (Veeva, Salesforce):** Deep integrations critical for adoption
- **Regulatory Environment (FDA, EMA):** No prohibitive AI regulations enacted
- **Customer IT Departments:** Timely SSO setup, integration support, security reviews

**Internal Dependencies:**
- **Fundraising Success:** Assume $3M-$5M seed round closed by Q1 2026
- **Hiring:** Ability to recruit and retain top engineering, sales, CS talent
- **Product Roadmap Execution:** Ship core features on time (Ask Expert, BYOAI, Mobile)
- **Customer Success Excellence:** Achieve 30-day time-to-value, >90% retention
- **Sales & Marketing:** Generate $12M+ pipeline to hit $1.2M ARR target

---

# PART III: APPENDICES

## Appendix A: Glossary of Terms

| Term | Definition |
|------|------------|
| **ARR** | Annual Recurring Revenue - predictable revenue from subscriptions |
| **ARPU** | Average Revenue Per User - ARR divided by number of customers |
| **BYOAI** | Bring Your Own AI - customer integrates proprietary AI agents |
| **CAC** | Customer Acquisition Cost - sales & marketing spend per customer |
| **CSAT** | Customer Satisfaction Score - rating (typically 1-5) of satisfaction |
| **GRR** | Gross Retention Rate - % of ARR retained excluding expansion |
| **LTV** | Lifetime Value - total revenue from customer over lifetime |
| **MSL** | Medical Science Liaison - field-based medical affairs professional |
| **NPS** | Net Promoter Score - likelihood to recommend (promoters - detractors) |
| **NRR** | Net Retention Rate - % of ARR retained including expansion |
| **RAG** | Retrieval-Augmented Generation - LLM grounded in factual documents |
| **SLA** | Service Level Agreement - contractual performance commitment |
| **TTV** | Time-to-Value - days from contract to measurable value |
| **WAU** | Weekly Active Users - unique users active in a given week |

---

## Appendix B: Reference Documents

**Strategic Documents:**
- `VITAL_PLATFORM_VISION_STRATEGY_GOLD_STANDARD.md` - Overall strategic vision
- `VITAL_ROI_BUSINESS_CASE.md` - Financial model and ROI analysis
- `VITAL_ANALYTICS_FRAMEWORK.md` - Measurement and metrics

**Agent Coordination:**
- `.claude/agents/AGENT_COORDINATION_GUIDE.md` - How agents work together
- `.claude/agents/QUICK_START_VISUAL_GUIDE.md` - Quick start for agents
- `.claude/agents/strategy-vision-architect.md` - Strategy agent definition
- `.claude/agents/business-analytics-strategist.md` - Business agent definition

**Product & Technical:**
- (PRD) - To be created by PRD Architect in Week 3-4
- (ARD) - To be created by System Architecture Architect in Week 4-6

---

## Appendix C: Stakeholder Contact Matrix

*[This section would include actual contact information for key stakeholders once project is live. Omitted here for privacy.]*

**Stakeholder Categories:**
- Executive Sponsors
- Project Team (Customer + VITAL)
- Technical Contacts (IT, Security)
- Business Owners (Medical Affairs Leadership)
- End Users (MSLs, Medical Directors)

---

## Appendix D: Change Log

| Date | Version | Author | Changes |
|------|---------|--------|---------|
| Nov 10, 2025 | 0.1 | Business & Analytics Strategist | Initial draft |
| Nov 12, 2025 | 0.5 | Business & Analytics Strategist | Added stakeholder analysis, compliance requirements |
| Nov 14, 2025 | 0.9 | Business & Analytics Strategist | Incorporated feedback from Strategy & Vision Architect |
| Nov 16, 2025 | 1.0 | Business & Analytics Strategist | Finalized for Week 1-2 deliverable |

---

**DOCUMENT STATUS: ✅ COMPLETE**

**Next Steps:**
1. Review by Strategy & Vision Architect (strategic alignment check)
2. Review by PRD Architect (product requirements alignment)
3. Review by Documentation & QA Lead (quality review)
4. Approval for use in product development (Week 3-4)

---

**END OF BUSINESS REQUIREMENTS DOCUMENT**

*Gold Standard Deliverable | VITAL Platform | November 2025*
